Vanguard Group Inc. Purchases 150,506 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE)

Vanguard Group Inc. increased its position in Pulse Biosciences, Inc. (NASDAQ:PLSE) by 15.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,146,339 shares of the company’s stock after purchasing an additional 150,506 shares during the quarter. Vanguard Group Inc. owned approximately 1.86% of Pulse Biosciences worth $19,958,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of PLSE. KLP Kapitalforvaltning AS acquired a new stake in shares of Pulse Biosciences in the fourth quarter valued at approximately $44,000. Farther Finance Advisors LLC boosted its holdings in shares of Pulse Biosciences by 44.4% during the 4th quarter. Farther Finance Advisors LLC now owns 7,220 shares of the company’s stock worth $126,000 after buying an additional 2,220 shares during the period. Bender Robert & Associates bought a new position in Pulse Biosciences in the 4th quarter valued at about $202,000. Charles Schwab Investment Management Inc. lifted its position in Pulse Biosciences by 0.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company’s stock worth $2,598,000 after acquiring an additional 1,092 shares during the last quarter. Finally, Oppenheimer & Co. Inc. acquired a new stake in Pulse Biosciences during the fourth quarter worth approximately $311,000. Institutional investors own 76.95% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a research note on Monday, March 31st.

Pulse Biosciences Price Performance

Pulse Biosciences stock opened at $16.89 on Thursday. Pulse Biosciences, Inc. has a 52 week low of $6.60 and a 52 week high of $25.00. The stock has a fifty day moving average of $17.49 and a 200-day moving average of $17.91.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.